In purified rat ␤-cells, the glucagon-receptor antagonist (10 mol/l) inhibited the effect of 1 nmol/l glucagon upon glucose-induced insulin release by 78 ؎ 6%. In the perfused rat pancreas, neither of these antagonists inhibited the potent secretory response to 20 mmol/l glucose, although they effectively suppressed the potentiating effect of, respectively, an infusion of glucagon (1 nmol/l) or GLP-1 (1 nmol/l) on insulin release. When endogenous glucagon release was enhanced by isoproterenol (100 nmol/l), no amplification was seen in the simultaneous or subsequent insulin secretory response to glucose. It is concluded that, at least under the present selected conditions, the glucose-induced insulin release by the perfused rat pancreas seems to occur independent of an amplifying glucagon signal from neighboring ␣-cells. Diabetes 51:669 -675, 2002
W
e have previously reported that the potent insulin secretory response to glucose is markedly diminished when pancreatic ␤-cells are isolated from the islet structure. A number of previous in vitro observations using isolated islets or purified islet cells have supported the idea that the amplitude of glucose stimulation of insulin release is strongly influenced by the intracellular cAMP level, which is regulated by various hormones and neurotransmitters (1) (2) (3) (4) (5) . It remained unclear, however, which agents provide the amplifying cAMP signals in physiological conditions (6) . There is sufficient evidence for a major role of glucagon in isolated islet preparations (1) (2) (3) 7) , which can potentiate glucose-induced insulin release via two different receptors (8) .
In vitro studies have indicated that separation of ␤-cells from ␣-cells explains in part the lower secretory activity of purified ␤-cells as compared with isolated islets (1, 2) . Locally released glucagon was indeed found to amplify glucose-induced insulin release in isolated islet cell preparations (1, 7, 8) . This also explains the higher secretory responsiveness of ␣-cell-containing islets isolated from the dorsal pancreatic lobe when compared with that of ␣-cell poor islets from the ventral lobe (5, 9) . It is conceivable that circulating glucagon levels influence the cAMP levels in ␤-cells in vivo. Other peptides, in particular glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, are likely candidates to contribute in this regulatory pathway through variations in their circulatory concentrations (3, 10) . In addition to this endocrine pathway, peptides such as glucagon may act via interstitial interactions. It is not yet possible to investigate such influences in the endocrine pancreas in vivo. Experiments have been undertaken in the isolated perfused pancreas to examine the possible role of ␣-cells on neighboring ␤-cells. These studies have indicated that islet blood flows in the direction from the ␤-cell core toward the non-␤-cell mantle (11, 12) . However, none of these data could provide final conclusions concerning interstitial glucagon interacting at sites where both ␣-and ␤-cells are in close contact.
As was suggested 10 years ago, specific glucagon-receptor antagonists would be required to assess the contribution of glucagon in the ␤-cell response to glucose (13) . Such antagonists would have the advantage over the previously used antibodies to glucagon in that they can penetrate into the interstitial space (14, 15) . In the present work, we examined the effect of a glucagon-receptor antagonist, [des-His 1 ,des-Phe 6 ,Glu 9 ]glucagon-NH 2 (16) , to assess the role of interstitial glucagon in the acute responsiveness to glucose of in situ pancreatic ␤-cells in the glucagon-rich dorsal part of the rat pancreas. Because high nanomolar glucagon concentrations were reported to activate GLP-1 receptors on ␤-cells (8), we also used a GLP-1-receptor antagonist, exendin-(9-39)-NH 2 (17) . Our data show that, at least in the condition of rat pancreas perfusion, there is little or no contribution of locally secreted glucagon to the acute secretory response of islet ␤-cells to glucose.
(1 min). Areas under the curve (AUC) in response to 20 mmol/l glucose stimulations (min 11-20, 36 -45 , and 61-70), with or without GLP-1/glucagon receptor agonists/antagonists (AUC 1 , AUC 2 , and AUC 3 ) or 100 nmol/l isoproterenol subtraction were calculated after basal insulin release at 1.4 mmol/l glucose. To adjust for the differences of the first glucose stimulation between different experiments, we expressed AUC 2 and AUC 3 as a percentage of AUC 1 . The potentiating effect of glucagon and GLP-1 and the effects of receptor antagonists were subsequently calculated by subtracting the response to glucose alone from the corresponding peak, in this way taking into account the memory effect of glucose alone. Statistical analysis. Data are expressed as mean values Ϯ SD of n independent experiments in the table and the text and as mean values Ϯ SE in the figures. Significance of differences between experimental conditions was assessed by the two-tailed Student's t tests. In the pancreas perfusions, the magnitude of the secretory response after the first glucose stimulation (AUC 1 ) was normally distributed for the 36 tested pancreata in our study (data not shown), validating the use of Student's t tests for further analysis. (24) , and on CHL cells stably transfected with the rat GLP-1-receptor gene (20) . Significant antagonism of 1 nmol/l glucagon-induced cAMP production in hepatocytes was noted between 0.3 mol/l peptide (17 Ϯ 5% inhibition; P Ͻ 0.005) and 10 mol/l (80% inhibition; P Ͻ 0.001). At 10 mol/l [des-His 1 ,des-Phe
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] glucagon-NH 2 , antagonism was almost complete at 0.1 nmol/l glucagon (97 Ϯ 1% inhibition; P Ͻ 0.005) but became nonsignificant at 10 nmol/l glucagon. The overall effect was a shift of the concentration response curve to the right (Fig. 1A) , resulting in higher apparent EC 50 for glucagon (12 Ϯ 4 nmol/l) than in control cells (EC 50 ϭ 0.9 Ϯ 0.4 nmol/l; P Ͻ 0.05). We previously reported that 1 mol/l exendin-(9-39)-NH 2 had no effect on glucagoninduced cAMP production by rat hepatocytes (8) .
In CHL cells expressing rat GLP-1 receptors, cAMP content was elevated 4.5 Ϯ 0.3 times by 1 nmol/l glucagon (Fig. 1B) ; n ϭ 4; P Ͻ 0.02). As shown previously (8) , this glucagon concentration was not affected by 1 mol/l exendin-(9-39)-NH 2 , whereas on the contrary, exendin-(9-39)-NH 2 could inhibit the potentiating effect of 10 nmol/l glucagon by Ͼ40% (8) . ]glucagon-NH 2 or exendin-(9-39)-NH 2 on glucose-induced insulin release. Having characterized the molecular tools to block glucagon activation of glucagon-and GLP-1-receptors on ␤-cells, we next assessed their effect on glucose-induced insulin release from the isolated perfused rat pancreas. As expected (25) , 20 mmol/l glucose stimulation resulted in biphasic insulin secretory response ( Fig. 2A) , with a rapid return to basal values when glucose was lowered to 1.4 mmol/l. Using a protocol with three successive 10-min glucose stimulation periods alternated by 15-min intervals of basal glucose (Fig. 2) , we observed that the second glucose stimulation resulted in a 1.5 Ϯ 0.2-fold larger insulin secretory response than the first stimulation (AUC 1 561 Ϯ 191 ng vs. AUC 2 819 Ϯ 275 ng; n ϭ 4; P Ͻ 0.02). As is shown in Fig. 2A , the mean secretory response to the third glucose stimulation was again 30% higher than the second (AUC 3 1,044 Ϯ 395 ng; P Ͻ 0.05). These results are compatible with a glucose memory effect described by Grill et al. (26, 27) . The potent insulin secretory response to glucose-on average 55 Ϯ 18 ng/min for the first glucose stimulation, 80 Ϯ 27 ng/min for the second, and 102 Ϯ 39 ng/min for the third-occurred in the presence of an undetectable pancreatic glucagon output before or during the 20 mmol/l glucose stimulation (Ͻ6 pmol/l). To investigate whether locally released glucagon may have influenced the observed secretory responsiveness, we added a second series of perfusions, the glucagon receptor antagonist [des-His 1 ,des-Phe 6 ,Glu 9 ]glucagon-NH 2 (10 mol/l) to the perfusion medium 15 min before and until the end of the second period of glucose stimulation. This addition had no effect on the time kinetics and magnitude of glucose-stimulated insulin release (Fig. 2B) because AUC 2 was again 1.3 Ϯ 0.2-fold higher (905 Ϯ 166 ng) than the AUC 1 caused by the first stimulation (682 Ϯ 75 ng; P ϭ 0.05). Furthermore, as in the control experiment, the third glucose stimulation, performed in the absence of the glucagon-receptor antagonist, resulted in 1.4 Ϯ 0.3-fold higher release (AUC 3 1,290 Ϯ 319 ng) than the second glucose stimulation (mean Ϯ SD, n ϭ 4; P ϭ 0.056).
The absence of an antagonizing effect of [des-His 1 ,desPhe 6 ,Glu 9 ]glucagon-NH 2 might be attributable to the presence of local glucagon levels above 10 nmol/l, in which range the antagonist was found to be ineffective. However, such local levels should have been detected in the effluent. Furthermore, at such high concentrations, glucagon is known to activate ␤-cells via GLP-1 receptors (8), which would have resulted in exendin-(9-39)-NH 2 antagonizing such effects, and this was not the case (Fig. 2C) . Therefore, neither the presence of the glucagon-receptor antagonist [des-His 1 ,des-Phe 6 ,Glu 9 ]glucagon-NH 2 nor that of the GLP-1 receptor antagonist exendin-(9-39)-NH 2 could affect the amplitude and time kinetics of glucose-induced insulin secretory response from the perfused glucagon-rich lobe of the rat pancreas. This could mean either that these antagonists do not block their respective receptors on ␤-cells because they are degraded before binding occurs or that occupancy of glucagon-and/or GLP-1-receptors with endogenous glucagon is very low in the studied conditions. (Fig. 2) , we added in a new series of experiments with exogenous glucagon or GLP-1 in the presence or absence of antagonist (Table 1) . Glucagon (1 nmol/l) potentiated the second glucose stimulation more than twofold (AUC 2 as % of AUC 1 : 1 nmol/l glucagon 300 Ϯ 4, n ϭ 12, vs. control 146 Ϯ 16, n ϭ 4; P Ͻ 0.001). Taking into account the memory effect of glucose alone, a second combined glucagon/glucose stimulation resulted in a 57% larger insulin output than the first glucagon/glucose stimulation (AUC 3 as % of AUC 1 : 1 nmol/l glucagon 427 Ϯ 65, n ϭ 4, vs. control 185 Ϯ 14, n ϭ 4; P Ͻ 0.01). Presence of the glucagon-receptor antagonist [des-His 1 ,des-Phe 6 ,Glu 9 ] glucagon-NH 2 prevented 81 Ϯ 10% of this potentiating effect of glucagon on insulin release during the third stimulation with glucose (AUC 3 as % of AUC 1 : 230 Ϯ 21 in the presence vs. 427 Ϯ 65 in the absence of antagonist, n ϭ 4; P Ͻ 0.002). In contrast, we observed no antagonism of the glucagon-potentiation of glucose-induced insulin release using 1 mol/l exendin-(9-39)-NH 2 (AUC 3 as % of AUC 1 : 389 Ϯ 61 in the presence vs. 427 Ϯ 65 in the absence of antagonist, n ϭ 4; not significant). As expected (28), 1 nmol/l GLP-1 potentiated glucose-induced insulin release more than threefold (AUC 2 as % of AUC 1 : 1 nmol/l GLP-1 500 Ϯ 66 ng, n ϭ 8, vs. control 146 Ϯ 16, n ϭ 4; P Ͻ 0.001). Similar to the gain in secretory response after repeated glucagon/glucose stimulation, the second GLP-1/glucose exposure of the pancreas resulted in a 58% more efficient amplification of the glucose-induced insulin release (AUC 3 as % of AUC 1 : 1 nmol/l GLP-1 742 Ϯ 94, n ϭ 4, vs. control 185 Ϯ 14, n ϭ 4) than the first GLP-1 addition (P Ͻ 0.002). This second GLP-1 stimulation was antagonized by 89 Ϯ 9% (P Ͻ 0.0001) by simultaneous perfusion with exendin-(9-39)-NH 2 . Therefore, the present data indicate that both [des-His 1 ,des-Phe 6 ,Glu 9 ]glucagon-NH 2 and exendin-(9-39)-NH 2 effectively antagonize the effect of, respectively, glucagon on glucagon receptors and GLP-1 on GLP-1-receptors. Together with the data in Fig. 2 , these results suggest that the glucose-induced insulin release from the perfused pancreas can occur in the absence of significant activity of occupied glucagon-and/or GLP-1-receptors. Effect of ␣-cell stimulation on glucose-induced insulin release. To investigate the possible contribution of local glucagon to glucose-induced insulin secretion in a condition of elevated glucagon release, we performed a perfusion experiment in which the second glucose stimulation and the 15 min preceding this period were supplemented with 100 nmol/l isoproterenol (Fig. 3) . This ␤-adrenergic agonist has been shown to stimulate directly the glucagon release from rat ␣-cells, without affecting insulin secretion from ␤-cells (4). Furthermore, in contrast to the effects observed in humans whereby the potentiation of glucose-induced insulin release by isoproterenol is strong (29) , interaction between isoproterenol and glucose at the level of insulin release has been reported to be weak and both stimulatory and inhibitory in the rat perfused pancreas (30, 31) . As could be expected (4, 32) , perfusion with 100 nmol/l isoproterenol induced a strong glucagon secretory response at 1.4 mmol/l glucose, with a maximal release of 0.24 ng/min that was at least fivefold above basal and returned to levels below the detection limit at 40 min (Fig. 3) . This resulted in an AUC of 1.7 Ϯ 0.4 ng glucagon and no detectable insulin during the 15-min perfusion with 1.4 mmol/l glucose and 100 nmol/l isoproterenol. Despite this previous elevated glucagon secretion, glucoseinduced insulin secretion was not augmented as compared with the control experiment without isoproterenol (AUC 2 ϭ 148 Ϯ 18% of AUC 1 in the presence vs. 146 Ϯ 16% in the absence of isoproterenol, n ϭ 4; not significant). Furthermore, glucagon remained elevated for 3 min more during the 20 mmol/l glucose stimulation, resulting in an average glucagon level of 0.09 Ϯ 0.02 ng/min (10 pmol/l). Because locally secreted glucagon is diluted into the islet blood flow, which represents in itself only 10% of the total pancreatic blood flow (33), we can assume that locally these glucagon concentrations may rise up to at least 100 pmol/l. We have previously shown that such glucagon concentration can significantly potentiate glucose-induced insulin secretion (1) . However, during this period of elevated pancreatic glucagon output (min 37-39) (Fig. 3) , glucose-induced insulin secretion was not significantly altered. In isoproterenol-stimulated pancreata, insulin re- lease during this period (298 Ϯ 115 ng) was 1.5 Ϯ 0.1-fold higher than release during the comparable period of the first glucose stimulation (193 Ϯ 76 ng). This memory effect was similar to control pancreata ( Fig. 2A) , from which release during min 37-39 (224 Ϯ 103 ng) was 1.4 Ϯ 0.3-fold higher than that observed during the first 3 min of the first glucose stimulation (158 Ϯ 59 ng).
Together, our results indicate that an episode of stimulated glucagon release, before or during glucose stimulation, does not potentiate the insulin response from the pancreas, further supporting the idea that locally secreted glucagon may not play a role in the responsiveness of pancreatic ␤-cells to glucose through interstitial interactions.
DISCUSSION
In rats and mice, ␤-cells are located in the islet center, whereas the non-␤-cells are situated in the islet mantle (34) . For the dorsal rat pancreas, which contains most glucagon cells of the gland, this means that the ␤-cell core of the islet is surrounded by a mantle of glucagon-secreting and somatostatin-secreting cells (9, 35) . Because both glucagon and somatostatin exert powerful effects on the glucose response of isolated rat ␤-cells (1,36) , the possibility was proposed that local (paracrine) interactions of glucagon and somatostatin with islet ␤-cells modulate the secretory response of the pancreas to elevated glucose (37) . The data in the present study suggest that the strong insulin secretory response to glucose of the isolated perfused pancreas can occur in the absence of interstitial influences by locally secreted glucagon. A potent insulin secretory response of ␤-cells to glucose was demonstrated in the isolated rat perfused pancreas in a condition of glucagon levels Ͻ6 pmol/l in the pancreatic effluent. However, locally secreted glucagon is diluted first in the islet blood circulation and subsequently in the total pancreatic blood circulation. Furthermore, in vivo normal blood glucagon levels are reported to be between 1 and 100 pmol/l (38 -40), whereas 1 pmol/l glucagon is enough to stimulate significantly insulin secretion from the perfused rat pancreas (41) . The use of a specific glucagonand GLP-1-receptor antagonist, [des-His 1 ,des-Phe 6 ,Glu 9 ] glucagon-NH 2 and exendin-(9-39)-NH 2 respectively, allowed us to assess interstitial influences of locally secreted glucagon, because these antagonists can enter the interstitial space (14, 15) .
We demonstrate here that [des-His 1 ,des-Phe glucagon-NH 2 for the glucagon receptors. In a concentration-response experiment performed with hepatocytes (data not shown), we observed concentration-dependent effects of the antagonist on 1 nmol/l glucagon-induced cAMP production. Because of solubility and pH effects on the buffers, we could not use concentrations Ͼ10 mol/l. This concentration could significantly antagonize glucagon concentrations up to 1 nmol/l in hepatocytes (Fig. 1A) . However, if higher glucagon levels exist locally, it could be expected that, in addition to glucagon receptors, GLP-1 receptors will be activated (8) . Therefore, 1 mol/l exendin-(9-39)-NH 2 was used in parallel (Fig. 2C) . Because glucagon amplifies 20 mmol/l glucose-induced insulin release (1, 8) , perfusion of the pancreas with either [desHis 1 ,des-Phe 6 ,Glu 9 ]glucagon-NH 2 or exendin-(9-39)-NH 2 should result in a lower glucose-induced insulin secretory response than in the control pancreas on the condition that local glucagon can activate ␤-cells. That we did not observe any inhibition of the pancreatic glucose-induced insulin response by either antagonist indicates that if glucagon interacts with ␤-cells, then it occurs after dilution in the general circulation (42, 43) , i.e., after at least one passage through the liver. Therefore, the lack of measurable glucagon levels in the pancreatic effluent may be explained by an extremely low glucagon secretion in the present experimental conditions. The observed effect of 1 nmol/l exogenous glucagon on insulin release (Table 1) further supports the absence of high glucagon concentrations influencing neighboring ␤-cells. This argument was already used by Kawai et al. (42) . It is unlikely that our negative results were caused by antagonist degradation before binding on their respective receptors. First, high concentrations were used, so degradation would have been extremely rapid. Second, [des-His 1 ,des-Phe 6 ,Glu 9 ] glucagon-NH 2 and exendin-(9-39)-NH 2 could block Ͼ80% of the insulin-stimulating effect of, respectively, 1 nmol/l glucagon and GLP-1 that was added to the perfusion medium. Positive controls for the action of these antagonists in the perfused pancreas were therefore obtained. The same degree of inhibition was also observed with hepatocytes stimulated with 1 nmol/l glucagon (Fig. 1A) , further supporting the idea that in the present model the used exogenous glucagon is not diluted extensively by endogenous glucagon.
The low rates of glucagon release under the chosen experimental conditions are a limitation of the present experimental system. We therefore induced glucagon release with the ␤-adrenergic agonist isoproterenol, a condition that is known to stimulate ␣-cells (4, 32) , while at the same time this agonist is not expected to stimulate ␤-cells directly (4). We observed that this condition did not potentiate the insulin secretory response of pancreatic ␤-cells to 20 mmol/l glucose, despite a clearly elevated rate of glucagon release before and during the first minutes of glucose stimulation. These observations further support the idea that the secretory response of the intact pancreas is not dependent on locally released glucagon. It is extremely difficult to rule out the possibility that tight junctions between neighboring cells seal off intercellular compartments where locally released glucagon is allowed to interact with receptors on ␤-cells. Considering our data (Fig. 3) , the release of such glucagon pools should not be isoproterenol-sensitive, which is very unlikely. It can thus be proposed that under the present conditions, local release of glucagon has no major effect on the magnitude of glucose-induced insulin release from the isolated rat pancreas. Extrapolation of these observations to in vivo conditions will require appropriate models to measure glucagon levels within the interstitial space, where it can potentiate insulin secretion.
In summary, our data demonstrate that the potent glucose-induced insulin release from the isolated perfused rat pancreas is not dependent on the priming effect of locally released glucagon, at least under the chosen experimental conditions. This both supports the view that islet blood flow direction is not from ␣-to ␤-cells (11) and indicates that glucagon in the islet interstitium is not in contact with glucagon-and GLP-1-receptors on ␤-cells. If the present observations on isolated rat pancreas (where no evidence for interstitial glucagon is found) can be extrapolated to human pancreas, then these data can be relevant for the clinical development of glucagon-receptor antagonists (16) , which aim to suppress glucagon-stimulated liver metabolism rather than glucose-induced insulin secretion.
